ArticleCancer cell2025
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis.
Abstract read
In one paragraph
Article in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Targeting a Myeloid-Regulatory B Cell Network Reverses Immune Paralysis in Periprosthetic Joint Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Inhibiting CXCL12/CXCR4 axis enhances T cell activity in gastric cancer.Cancer gene therapy · 2026Article
- Myeloid cell reprogramming combined with zoledronic acid effectively suppresses bone metastasis.Cancer biology & medicine · 2026Article
- Article
- Expression profiling, molecular subtyping and prognostic signature construction of chemokines and chemokine receptors in gastric cancer.Translational cancer research · 2026Article
- Targeting cytokine/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Review
- Albumin-Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy.Nature cancer · 2026Article
- Multi-Omics reveals SPP1 + malignant and CXCR4Discover oncology · 2026Article
- Single-cell and spatial transcriptomics reveal that the CXCL12-CXCR4 axis drives the immune-desert phenotype in small cell lung cancer by recruiting immunosuppressive CXCR4Journal for immunotherapy of cancer · 2026Article
- Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance.Molecular cancer · 2026Review
- Understanding the link between PMN-MDSCs and CXCL8-CXCR1/2 axis in primary myelofibrosis.Frontiers in cell and developmental biology · 2026Article
- Nanosystem-Mediated Intercellular Crosstalk Modulation in the Tumor Microenvironment for Enhanced Cancer Immunotherapy.Drug design, development and therapy · 2026Review
- Crosstalk between NRP1 and autophagy in the tumor microenvironment: from molecular mechanisms to therapeutic targeting.Frontiers in immunology · 2026Review
- From bone marrow to the tumor microenvironment: how neutrophil maturation shapes cancer immunity.Cancer biology & medicine · 2025Article
- A pan-cancer single-cell analysis reveals the effect of PD-1 blockades on tumor angiogenesis by inhibiting the endothelial CXCL12-CXCR4 axis.Cancer immunology, immunotherapy : CII · 2025Article
- Modeling the pre-metastatic niche of gastric cancer peritoneal metastasis under spatiotemporal resolution and investigating EVs-mediated immune suppression.Frontiers in immunology · 2025Review
Corrections and comments
- Update of
Authors and funding
22 authors.
Jin QianDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Chenkai MaIntegrated Diagnostic, Human Health, Health and Biosecurity, CSIRO, Westmead, NSW 2070, Australia.
Quin T WaterburyDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Xiaofei ZhiDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA; Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Christine S MoonDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA; Department of Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA.
Ruhong TuDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, China.
Hiroki KobayashiDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Feijing WuDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Biyun ZhengDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA; Department of Gastroenterology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, China.
Yi ZengDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Hualong ZhengDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Yosuke OchiaiDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Ruth A WhiteDivision of Hematology and Medical Oncology, NYU Langone's Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA.
David W HarleDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Jonathan S LaBellaDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Leah B ZamechekDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA.
Lucas ZhongMing HuDepartment of Systems Biology, Columbia University Medical Center, New York, NY 10032, USA.
Ryan H MoyDivision of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
Arnold S HanDepartment of Microbiology and Immunology, Columbia University, New York, NY 10032, USA.
Bruce L DaughertyTonix Pharmaceuticals, Inc., Chatham, NJ 07928, USA.
Seth LedermanTonix Pharmaceuticals, Inc., Chatham, NJ 07928, USA.
Timothy C WangDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Research Center, Columbia University Medical Center, New York, NY 10032, USA; Columbia University Digestive and Liver Diseases Research Center, Columbia University, New York, NY 10032, USA. Electronic address: tcw21@cumc.columbia.edu.
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MThe Role of Stem Cells and the Microenvironment in Gastrointestinal CancersR35CA210088 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Timothy Cragin Wang · 2017 to 2026
$10.2MNUTRITIONT32DK007647 · NIDDK · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anthony W Ferrante, Lori M Zeltser · 1990 to 2026
$7.4MThe Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Robert F. Schwabe · 2022 to 2026
$7.2MGastroesophageal junction stem cells as the origin of Barretts esophagus and cancerR01CA272901 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI QUE, JIANWEN, WANG, TIMOTHY CRAGIN · 2022 to 2025
$4.9MMultidisciplinary Training in Gastrointestinal CancersT32CA285274 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Julian Abrams, Anil K Rustgi · 2024 to 2026
$897kNCATS NIH HHS UL1 TR001873NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA272901NCI NIH HHS R35 CA210088NCI NIH HHS T32 CA285274NIDDK NIH HHS P30 DK132710NIDDK NIH HHS T32 DK007647
Abstract
Pathologically activated immunosuppressive neutrophils impair cancer immunotherapy efficacy. The chemokine receptor CXCR4, a central regulator of hematopoiesis and neutrophil biology, represents an attractive target. Here, we fuse a secreted CXCR4 partial agonist, trefoil factor 2 (TFF2), to mouse serum albumin (MSA) and demonstrate that TFF2-MSA peptide synergizes with anti-PD-1 to inhibit primary tumor growth and distant metastases and prolongs survival in gastric cancer (GC) mouse models. Using histidine decarboxylase (Hdc)-GFP transgenic mice to track polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) in vivo, we find that TFF2-MSA selectively reduces the Hdc-GFP
Indexed as
GranulocytesImmunotherapyNeutrophilsReceptors, CXCR4Stomach NeoplasmsAnimalsCell Line, TumorHumansMiceMice, Inbred C57BLMice, TransgenicMyeloid-Derived Suppressor CellsCXCR4 protein, humanCXCR4 protein, mouseReceptors, CXCR4CXCR4gastric cancergranulopoiesisimmunosuppressive neutrophilMDSCpartial agonistpolymorphonuclear myeloid-derived suppressor cellsTFF2
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.